Literature DB >> 18498538

Pathogenesis of asthma.

Stephen T Holgate.   

Abstract

While asthma is considered an inflammatory disorder of the conducting airways, it is becoming increasingly apparent that the disease is heterogeneous with respect to immunopathology, clinical phenotypes, response to therapies, and natural history. Once considered purely an allergic disorder dominated by Th2-type lymphocytes, IgE, mast cells, eosinophils, macrophages, and cytokines, the disease also involves local epithelial, mesenchymal, vascular and neurologic events that are involved in directing the Th2 phenotype to the lung and through aberrant injury-repair mechanisms to remodeling of the airway wall. Structural cells provide the necessary "soil" upon which the "seeds" of the inflammatory response are able to take root and maintain a chronic phenotype and upon which are superimposed acute and subacute episodes usually driven by environmental factors such as exposure to allergens, microorganisms, pollutants or caused by inadequate antiinflammatory treatment. Greater consideration of additional immunologic and inflammatory pathways are revealing new ways of intervening in the prevention and treatment of the disease. Thus increased focus on environmental factors beyond allergic exposure (such as virus infection, air pollution, and diet) are identifying targets in structural as well as immune and inflammatory cells at which to direct new interventions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18498538     DOI: 10.1111/j.1365-2222.2008.02971.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  217 in total

Review 1.  Emerging roles of T helper subsets in the pathogenesis of asthma.

Authors:  Douglas M Durrant; Dennis W Metzger
Journal:  Immunol Invest       Date:  2010       Impact factor: 3.657

2.  Epoxyeicosatrienoic acids are involved in the C(70) fullerene derivative-induced control of allergic asthma.

Authors:  Sarah K Norton; Dayanjan S Wijesinghe; Anthony Dellinger; Jamie Sturgill; Zhiguo Zhou; Suzanne Barbour; Charles Chalfant; Daniel H Conrad; Christopher L Kepley
Journal:  J Allergy Clin Immunol       Date:  2012-06-02       Impact factor: 10.793

3.  Oxidant signaling for interleukin-13 gene expression in lung smooth muscle cells.

Authors:  Geetanjali Bansal; Chi-Ming Wong; Lingling Liu; Yuichiro J Suzuki
Journal:  Free Radic Biol Med       Date:  2012-02-25       Impact factor: 7.376

Review 4.  Janus kinase-3 dependent inflammatory responses in allergic asthma.

Authors:  Rama Malaviya; Debra L Laskin; Ravi Malaviya
Journal:  Int Immunopharmacol       Date:  2010-04-27       Impact factor: 4.932

Review 5.  Pro/Con debate: Is occupational asthma induced by isocyanates an immunoglobulin E-mediated disease?

Authors:  A V Wisnewski; M Jones
Journal:  Clin Exp Allergy       Date:  2010-06-07       Impact factor: 5.018

6.  Simvastatin inhibits goblet cell hyperplasia and lung arginase in a mouse model of allergic asthma: a novel treatment for airway remodeling?

Authors:  Amir A Zeki; Jennifer M Bratt; Michelle Rabowsky; Jerold A Last; Nicholas J Kenyon
Journal:  Transl Res       Date:  2010-12       Impact factor: 7.012

7.  Metabolic alterations in the sera of Chinese patients with mild persistent asthma: a GC-MS-based metabolomics analysis.

Authors:  Chun Chang; Zhi-guo Guo; Bei He; Wan-zhen Yao
Journal:  Acta Pharmacol Sin       Date:  2015-11       Impact factor: 6.150

Review 8.  Pathogenetic and prognostic roles of bloodborne fibrocytes in asthma.

Authors:  Sabrina Mattoli
Journal:  J Zhejiang Univ Sci B       Date:  2015-08       Impact factor: 3.066

Review 9.  Where asthma and hypersensitivity pneumonitis meet and differ: noneosinophilic severe asthma.

Authors:  Pieter Bogaert; Kurt G Tournoy; Thomas Naessens; Johan Grooten
Journal:  Am J Pathol       Date:  2008-12-12       Impact factor: 4.307

10.  Eosinophils and their interactions with respiratory virus pathogens.

Authors:  Helene F Rosenberg; Kimberly D Dyer; Joseph B Domachowske
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.